Johnson & Johnson (JNJ) Announced the European launch of Its Shockwave Javelin Peripheral IVL Catheter

Johnson & Johnson (NYSE:JNJ) is one of the 15 Best Stocks to Invest in for Financial Stability.

On September 15, 2025, Johnson & Johnson (NYSE:JNJ) announced the European launch of its Shockwave Javelin Peripheral IVL Catheter, which is a groundbreaking platform to treat peripheral artery disease (PAD).

The Forward IVL System, which features a single distal emitter placed behind the catheter tip, addresses “device-uncrossable” calcified lesions below the knee-one of the most difficult challenges in PAD treatment. Furthermore, clinical results from the FORWARD PADE IDE trial reassured the catheter’s safety and effectiveness. The results also matched legacy Shockwave IVL devices while offering improved lesion access. This innovation strengthens Johnson & Johnson (NYSE:JNJ)’s position in intravascular lithotripsy and expands treatment options for patients facing life-altering risks, as PAD and chronic limb-threatening ischemia impact millions globally.

Johnson & Johnson (NYSE:JNJ), a global healthcare company, innovates in medicines and medtech to prevent, treat, and cure complex diseases with smarter, less invasive, and personalized solutions for patients globally. It is one of the Best Stocks To Buy.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.